Psilocybin for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 21 Jun 2021: Trial registered, NCT04932434
  2. 15 Aug 2021: Trial started, NCT04932434
  3. 28 May 2026: Trial registered, NCT07610369
  4. 10 Jul 2026: Trial started, NCT07610369

The trials

NCT04932434: Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

State
Completed
Phase
Phase 2
People
12 taking part
Started
15 Aug 2021
Primary completion
31 Dec 2024
Arms
Psilocybin therapy
Results
Posted on the registry
  1. 21 Jun 2021: Trial registered
  2. 15 Aug 2021: Trial started
  3. 31 Dec 2024: Trial completed
  4. 3 Sep 2026: Trial results posted

NCT07610369: The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

State
Under way
Phase
Phase 2
People
40 planned
Started
10 Jul 2026
Primary completion
Jul 2030
Arms
Psilocybin Administration Session 1, Psilocybin Administration Session 2
Results
None posted
  1. 28 May 2026: Trial registered
  2. 10 Jul 2026: Trial started

How the status changed

  1. 16 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as High Dose Psilocybin, Low Dose Psilocybin, Medium Dose Psilocybin, Psilocybin (0.25mg/kg), Psilocybin (Usona Institute), Psilocybin (drug), Psilocybin 100 mcg/kg, Psilocybin 25 mg, Psilocybin 25 mg per os, Psilocybin 25mg, Psilocybin assisted therapy, Psilocybin first, Psilocybin plus Visual Healing Set and Setting, Psilocybin therapy, psilocybin 25 mg sod.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.